Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2019 | Aug. 10, 2019 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | BIOC | |
Entity Registrant Name | BIOCEPT INC | |
Entity Central Index Key | 0001044378 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity File Number | 001-36284 | |
Entity Tax Identification Number | 800943522 | |
Entity Address, Address Line One | 5810 Nancy Ridge Drive | |
Entity Address, City or Town | San Diego | |
Entity Address, State or Province | California | |
Entity Address, Postal Zip Code | 92121 | |
City Area Code | 858 | |
Local Phone Number | 320-8200 | |
Entity Common Stock, Shares Outstanding | 23,018,235 |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash | $ 12,590,597 | $ 3,423,373 |
Accounts receivable, net | 2,208,955 | 1,574,325 |
Inventories, net | 605,472 | 587,222 |
Prepaid expenses and other current assets | 586,267 | 425,961 |
Total current assets | 15,991,291 | 6,010,881 |
Fixed assets, net | 1,219,103 | 2,739,422 |
Lease right-of-use assets | 2,694,446 | |
Total assets | 19,904,840 | 8,750,303 |
Current liabilities: | ||
Accounts payable | 2,020,580 | 2,039,718 |
Accrued liabilities | 1,490,808 | 1,928,393 |
Supplier financings | 264,069 | |
Current portion of equipment financings | 641,536 | |
Current portion of lease liabilities | 2,046,413 | |
Total current liabilities | 5,821,870 | 4,609,647 |
Non-current portion of equipment financings | 985,015 | |
Non-current portion of lease liabilities | 983,419 | |
Non-current portion of deferred rent | 113,122 | |
Total liabilities | 6,805,289 | 5,707,784 |
Commitments and contingencies (see Note 11) | ||
Shareholders’ equity: | ||
Preferred stock, $0.0001 par value, 5,000,000 authorized; 4,417 shares issued and outstanding at December 31, 2018; and 2,133 shares issued and outstanding at June 30, 2019. | ||
Common stock, $0.0001 par value, 150,000,000 authorized; 4,629,174 issued and outstanding at December 31, 2018; 23,018,235 issued and outstanding at June 30, 2019. | 2,302 | 463 |
Additional paid-in capital | 247,387,369 | 223,499,634 |
Accumulated deficit | (234,290,120) | (220,457,578) |
Total shareholders’ equity | 13,099,551 | 3,042,519 |
Total liabilities and shareholders’ equity | $ 19,904,840 | $ 8,750,303 |
Condensed Balance Sheets (Paren
Condensed Balance Sheets (Parenthetical) - $ / shares | Jun. 30, 2019 | Dec. 31, 2018 |
Statement Of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 2,133 | 4,417 |
Preferred stock, shares outstanding | 2,133 | 4,417 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
Common stock, shares issued | 23,018,235 | 4,629,174 |
Common stock, shares outstanding | 23,018,235 | 4,629,174 |
Condensed Statements of Operati
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Statement [Abstract] | ||||
Net revenues | $ 1,191,323 | $ 822,238 | $ 2,215,562 | $ 1,629,181 |
Costs and expenses: | ||||
Cost of revenues | 2,673,323 | 2,699,671 | 5,272,687 | 5,134,557 |
Research and development expenses | 1,148,280 | 1,019,285 | 2,371,571 | 2,089,866 |
General and administrative expenses | 1,676,310 | 1,708,970 | 3,358,147 | 3,647,634 |
Sales and marketing expenses | 1,614,732 | 1,433,174 | 2,989,292 | 3,069,716 |
Total costs and expenses | 7,112,645 | 6,861,100 | 13,991,697 | 13,941,773 |
Loss from operations | (5,921,322) | (6,038,862) | (11,776,135) | (12,312,592) |
Other income/ (expense): | ||||
Interest expense | (63,574) | (84,239) | (125,548) | (166,913) |
Warrant inducement and other expenses | (1,831,116) | (30,000) | (1,831,116) | (30,000) |
Total other income/ (expense): | (1,894,690) | (114,239) | (1,956,664) | (196,913) |
Loss before income taxes | (7,816,012) | (6,153,101) | (13,732,799) | (12,509,505) |
Income tax expense | (739) | |||
Net loss and comprehensive loss | (7,816,012) | (6,153,101) | (13,732,799) | (12,510,244) |
Deemed dividend related to warrants down round provision | (99,743) | |||
Net loss attributable to common shareholders | $ (7,816,012) | $ (6,153,101) | $ (13,832,542) | $ (12,510,244) |
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders: | ||||
Basic | 20,466,224 | 2,280,115 | 16,670,184 | 2,096,717 |
Diluted | 20,466,224 | 2,280,115 | 16,670,184 | 2,096,717 |
Net loss per common share: | ||||
Basic | $ (0.38) | $ (2.70) | $ (0.83) | $ (5.97) |
Diluted | $ (0.38) | $ (2.70) | $ (0.83) | $ (5.97) |
Condensed Statements of Shareho
Condensed Statements of Shareholders' Equity - USD ($) | Total | January 2019 Financing Transaction [Member] | February 2019 Financing Transaction [Member] | January 2019 Financing Transaction Overallotment [Member] | March 2019 Financing Transaction [Member] | Common Stock [Member] | Common Stock [Member]January 2019 Financing Transaction [Member] | Common Stock [Member]February 2019 Financing Transaction [Member] | Common Stock [Member]January 2019 Financing Transaction Overallotment [Member] | Common Stock [Member]March 2019 Financing Transaction [Member] | SeriesA Convertible Preferred Stock [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member]January 2019 Financing Transaction [Member] | Additional Paid-in Capital [Member]February 2019 Financing Transaction [Member] | Additional Paid-in Capital [Member]January 2019 Financing Transaction Overallotment [Member] | Additional Paid-in Capital [Member]March 2019 Financing Transaction [Member] | Accumulated Deficit [Member] |
Beginning balance at Dec. 31, 2017 | $ 1,296,034 | $ 118 | $ 196,545,523 | $ (195,249,607) | |||||||||||||
Beginning balance, shares at Dec. 31, 2017 | 1,181,179 | ||||||||||||||||
Stock-based compensation expense | 225,263 | 225,263 | |||||||||||||||
Shares and warrants issued, net of issuance costs | $ 13,342,821 | $ 110 | $ 13,342,711 | ||||||||||||||
Shares and warrants issued, net of issuance costs, shares | 1,095,153 | ||||||||||||||||
Adjustment for presentation after reverse stock split | $ 6,576 | (6,576) | |||||||||||||||
Net loss | (6,357,143) | (6,357,143) | |||||||||||||||
Ending balance at Mar. 31, 2018 | 8,506,975 | $ 6,804 | 210,106,921 | (201,606,750) | |||||||||||||
Ending balance, shares at Mar. 31, 2018 | 2,276,332 | ||||||||||||||||
Beginning balance at Dec. 31, 2017 | 1,296,034 | $ 118 | 196,545,523 | (195,249,607) | |||||||||||||
Beginning balance, shares at Dec. 31, 2017 | 1,181,179 | ||||||||||||||||
Net loss | (12,510,244) | ||||||||||||||||
Ending balance at Jun. 30, 2018 | 2,527,568 | $ 6,823 | 210,280,596 | (207,759,851) | |||||||||||||
Ending balance, shares at Jun. 30, 2018 | 2,282,166 | ||||||||||||||||
Beginning balance at Dec. 31, 2017 | 1,296,034 | $ 118 | 196,545,523 | (195,249,607) | |||||||||||||
Beginning balance, shares at Dec. 31, 2017 | 1,181,179 | ||||||||||||||||
Net loss | (24,600,000) | ||||||||||||||||
Ending balance at Dec. 31, 2018 | 3,042,519 | $ 463 | 223,499,634 | (220,457,578) | |||||||||||||
Ending balance, shares at Dec. 31, 2018 | 4,629,174 | 4,417 | |||||||||||||||
Beginning balance at Mar. 31, 2018 | 8,506,975 | $ 6,804 | 210,106,921 | (201,606,750) | |||||||||||||
Beginning balance, shares at Mar. 31, 2018 | 2,276,332 | ||||||||||||||||
Stock-based compensation expense | 173,694 | 173,694 | |||||||||||||||
Shares issued for restricted stock units | $ 19 | (19) | |||||||||||||||
Shares issued for restricted stock units, shares | 5,834 | ||||||||||||||||
Net loss | (6,153,101) | (6,153,101) | |||||||||||||||
Ending balance at Jun. 30, 2018 | 2,527,568 | $ 6,823 | 210,280,596 | (207,759,851) | |||||||||||||
Ending balance, shares at Jun. 30, 2018 | 2,282,166 | ||||||||||||||||
Beginning balance at Dec. 31, 2018 | 3,042,519 | $ 463 | 223,499,634 | (220,457,578) | |||||||||||||
Beginning balance, shares at Dec. 31, 2018 | 4,629,174 | 4,417 | |||||||||||||||
Stock-based compensation expense | 102,459 | 102,459 | |||||||||||||||
Shares issued upon exercise of common stock warrants | 4,748 | $ 1 | 4,747 | ||||||||||||||
Shares issued upon exercise of common stock warrants, shares | 5,985 | ||||||||||||||||
Deemed dividends related warrants down round provision | 99,743 | (99,743) | |||||||||||||||
Shares and warrants issued, net of issuance costs | $ 2,032,311 | $ 6,602,735 | $ 592,306 | $ 7,553,793 | $ 99 | $ 625 | $ 54 | $ 595 | $ 2,032,212 | $ 6,602,110 | $ 592,252 | $ 7,553,198 | |||||
Shares and warrants issued, net of issuance costs, shares | 990,000 | 6,250,000 | 538,867 | 5,950,000 | |||||||||||||
Shares issued upon conversion of preferred stock | $ 50 | (50) | |||||||||||||||
Shares issued upon conversion of preferred stock, shares | 503,438 | (2,278) | |||||||||||||||
Net loss | (5,916,787) | (5,916,787) | |||||||||||||||
Ending balance at Mar. 31, 2019 | 14,014,084 | $ 1,887 | 240,486,305 | (226,474,108) | |||||||||||||
Ending balance, shares at Mar. 31, 2019 | 18,867,464 | 2,139 | |||||||||||||||
Beginning balance at Dec. 31, 2018 | 3,042,519 | $ 463 | 223,499,634 | (220,457,578) | |||||||||||||
Beginning balance, shares at Dec. 31, 2018 | 4,629,174 | 4,417 | |||||||||||||||
Deemed dividends related warrants down round provision | 99,743 | ||||||||||||||||
Net loss | (13,732,799) | ||||||||||||||||
Ending balance at Jun. 30, 2019 | 13,099,551 | $ 2,302 | 247,387,369 | (234,290,120) | |||||||||||||
Ending balance, shares at Jun. 30, 2019 | 23,018,235 | 2,133 | |||||||||||||||
Beginning balance at Mar. 31, 2019 | 14,014,084 | $ 1,887 | 240,486,305 | (226,474,108) | |||||||||||||
Beginning balance, shares at Mar. 31, 2019 | 18,867,464 | 2,139 | |||||||||||||||
Stock-based compensation expense | 224,641 | 224,641 | |||||||||||||||
Shares issued upon exercise of common stock warrants | 4,845,722 | $ 415 | 4,845,307 | ||||||||||||||
Shares issued upon exercise of common stock warrants, shares | 4,149,445 | ||||||||||||||||
Shares issued upon conversion of preferred stock, shares | 1,326 | (6) | |||||||||||||||
Warrant inducement expense | 1,831,116 | 1,831,116 | |||||||||||||||
Net loss | (7,816,012) | (7,816,012) | |||||||||||||||
Ending balance at Jun. 30, 2019 | $ 13,099,551 | $ 2,302 | $ 247,387,369 | $ (234,290,120) | |||||||||||||
Ending balance, shares at Jun. 30, 2019 | 23,018,235 | 2,133 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Cash Flows from Operating Activities | ||
Net loss | $ (13,732,799) | $ (12,510,244) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 450,984 | 357,173 |
Amortization of right-of-use assets | (75,613) | |
Inventory reserve | 8,872 | (68,782) |
Stock-based compensation | 327,100 | 398,957 |
Warrant inducement expense | 1,831,116 | |
Non-cash interest expense related to credit facility and other financing activities | 31,454 | |
Increase/(decrease) in cash resulting from changes in: | ||
Accounts receivable, net | (634,630) | (244,239) |
Inventory | (27,122) | 30,447 |
Prepaid expenses and other current assets | 233,153 | 59,545 |
Accounts payable | (71,720) | 435,667 |
Accrued liabilities | (279,244) | 71,749 |
Accrued interest | 10,825 | |
Deferred rent | (54,886) | |
Net cash used in operating activities | (11,969,903) | (11,482,334) |
Cash Flows from Investing Activities: | ||
Purchases of fixed assets | (86,476) | (72,356) |
Net cash used in investing activities | (86,476) | (72,356) |
Cash Flows from Financing Activities: | ||
Net proceeds from issuance of common stock and warrants | 16,779,772 | 13,342,821 |
Proceeds from exercise of common stock warrants | 2,513,172 | 0 |
Proceeds from warrant exercise inducement, net | 2,337,298 | |
Payments on finance leases | (277,250) | (111,006) |
Payments on supplier and other third-party financings | (129,389) | (229,408) |
Payments on credit facility | (1,025,217) | |
Net cash provided by financing activities | 21,223,603 | 11,977,190 |
Net increase in Cash | 9,167,224 | 422,500 |
Cash at Beginning of Period | 3,423,373 | 2,146,611 |
Cash at End of Period | 12,590,597 | 2,569,111 |
Cash paid during the period for: | ||
Interest | $ 125,548 | 134,604 |
Income taxes | $ 739 |
Condensed Statements of Cash _2
Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) | Jan. 30, 2018 | May 31, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 |
Cancelled insurance premiums previously financed through third-parties, remaining principal outstanding balance | $ 31,000 | |||||
Financed insurance premium through third party financing | $ 393,000 | 488,000 | ||||
Financed insurance premium through third party financing, new policies | 80,000 | |||||
Fixed assets purchased under finance lease obligations | 149,000 | 104,000 | ||||
Purchases of fixed assets | 53,000 | 35,000 | $ 25,000 | $ 31,000 | ||
Exercise price of unregistered warrants | $ 1.20 | |||||
Class of warrant or rights, term | 5 years | |||||
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value | $ 9,700,000 | |||||
Offering fees and costs recorded within common stock issuance costs as an offset to additional paid in capital | 1,400,000 | |||||
Deemed dividends related warrants downround provision | $ 99,000 | 99,743 | ||||
Operating lease, right-of-use asset | 1,337,240 | |||||
Operating lease liability | 1,533,091 | |||||
Lease right-of-use assets | 1,357,206 | |||||
Number of common stock warrant exercised | 4,100,000 | |||||
Proceeds from exercise of common stock warrants | $ 4,800,000 | $ 2,513,172 | $ 0 | |||
Warrant Inducement Transaction [Member] | ||||||
Number of common stock warrant exercised | 2,100,000 | |||||
Proceeds from exercise of common stock warrants | $ 2,300,000 | |||||
Warrant [Member] | ||||||
Proceeds from exercise of common stock warrants | $ 2,500,000 | |||||
Maximum [Member] | ||||||
Exercise price of unregistered warrants | $ 1.20 | |||||
Minimum [Member] | ||||||
Exercise price of unregistered warrants | $ 1.25 | |||||
Follow-on Public Offering [Member] | ||||||
Public offering, number of common stock and warrants issued | 1,095,153 | |||||
Stock price | $ 13.50 | |||||
Exercise price of unregistered warrants | $ 1.20 | |||||
Class of warrant or rights, term | 5 years | |||||
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value | $ 9,700,000 | |||||
Proceeds from issuance of common stock, net of issuance costs | 13,300,000 | |||||
Proceeds from exercise of common stock warrants | $ 0 | |||||
Follow-on Public Offering [Member] | Maximum [Member] | ||||||
Issuance of warrants to purchase shares of common stock | 1,095,153 |
The Company, Business Activitie
The Company, Business Activities and Basis of Presentation | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
The Company, Business Activities and Basis of Presentation | 1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and effected a reincorporation to Delaware in July 2013. The Company is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC TM Further, sales to laboratory supply distributors of our proprietary blood collection tubes, or BCTs, commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. As such, all references to share and per share amounts in these unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the one-for-thirty reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 29, 2019 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss. Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Contracts For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and six months ended June 30, 2018 and 2019. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three and six-months ended June 30, 2018 and 2019, disaggregated by source and nature, are as follows: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Net revenues from contracted payers* $ 356,000 $ 489,901 $ 694,760 $ 971,320 Net revenues from non-contracted payers 414,742 628,477 828,851 1,125,847 Development services revenues 51,496 45,081 96,130 87,579 Kits and Blood Collection Tubes (BCT) — 27,864 9,440 30,816 Total net revenues $ 822,238 $ 1,191,323 $ 1,629,181 $ 2,215,562 *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Net commercial revenues recognized upon delivery $ 770,742 $ 1,118,378 $ 1,523,611 $ 2,009,364 Development services revenues recognized upon delivery 51,496 45,081 96,130 87,579 Commercial revenues recognized upon cash collection — — — 87,803 Kits and Blood Collection Tubes (BCT) — 27,864 9,440 30,816 Total net revenues $ 822,238 $ 1,191,323 $ 1,629,181 $ 2,215,562 Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2018 and 2019 were as follows: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Medicare and Medicare Advantage 38 % 43 % 39 % 45 % Blue Cross Blue Shield 12 % 20 % 17 % 17 % United Healthcare 15 % 8 % 19 % 10 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and June 30, 2019 were as follows: December 31, 2018 June 30, 2019 Blue Cross Blue Shield 22 % 23 % Medicare and Medicare Advantage 17 % 18 % United Healthcare 15 % 15 % Recent Accounting Pronouncements In February 2016, the FASB issued authoritative guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months be recognized on the balance sheet. The guidance is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2018. Effective January 1, 2019, the Company adopted the guidance and elected the optional transition method to account for the impact of the adoption with a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company also elected the practical expedient package as permitted under the transition guidance. As of January 1, 2019, the Company recorded a right-of-use asset and liability upon adoption of the guidance (See Note 7). In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity. In February 2018, the FASB issued authoritative guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from a tax bill, “H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018,” or the Tax Cuts and Jobs Act, enacted on December 22, 2017. These amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act. However, because these amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This guidance also requires certain disclosures about stranded tax effects. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 which did not have a material impact on its financial statements or disclosures because the Company does not currently maintain any stranded tax effects in accumulated other comprehensive income. In June 2018, the FASB issued authoritative guidance simplifying the accounting for nonemployee stock-based compensation and largely aligning such compensation with the accounting requirements for employee stock-based awards. For public companies, this guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures. In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606). The Company currently intends to adopt this guidance upon the effective date and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures. |
Liquidity and Going Concern Unc
Liquidity and Going Concern Uncertainty | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Liquidity and Going Concern Uncertainty | 2. Liquidity and Going Concern Uncertainty As of June 30, 2019, cash totaled $12.6 million and the Company had an accumulated deficit of $234.3 million. For the year ended December 31, 2018 and the six months ended June 30, 2019, the Company incurred net losses of $24.6 million and $13.7 million, respectively. At June 30, 2019, the Company had aggregate net interest-bearing indebtedness of $1.8 million, of which $899,000 was due within one year, in addition to $3.5 million of other non-interest bearing current liabilities. Additionally, in February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020, under which $216,000 remained outstanding at June 30, 2019 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. The accompanying financial statements and notes have been prepared assuming that the Company will continue as a going concern. The accompanying financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. On January 30, 2018, the Company received net cash proceeds of approximately $13.3 million from the closing of a follow-on public offering of 1,095,153 shares of its common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering, with approximately $1.3 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.20 per share, which is subject to down round adjustment, until their expiration in January 2023. Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 offering price per share in the February 2019 financing transaction. In May 2018, the SEC declared effective a shelf registration statement filed by the Company, which expires in May 2021. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as its public float is less than $75 million. On August 13, 2018, the Company completed a rights offering pursuant to an effective registration statement. Pursuant to the rights offering, the Company sold an aggregate of 11,587 units consisting of an aggregate of 11,587 shares of Series A Convertible Preferred Stock and 2,549,140 warrants, with each warrant exercisable for one share of its common stock at an exercise price of $4.53 per share, resulting in net proceeds to the Company of approximately $10.1 million, after deducting expenses relating to the Rights Offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. On September 20, 2018, the Company completed an offering of 642,438 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 120,000 shares of its common stock. The shares were sold at a purchase price of $3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to the Company from the offering were approximately $2.2 million, after deducting expenses related to the offering including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering initially had an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date. On January 18, 2019, the Company completed an offering of 990,000 shares of the Company’s common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses. On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million from the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. On March 19, 2019, the Company received net cash proceeds of approximately $7.5 million as a result of completing a registered direct offering of 5,950,000 shares at a negotiated purchase price of $1.37 per share. In May 2019, the Company received net proceeds of approximately $2.3 million related to the May 2019 Warrant Exercise Inducement Offering as well as an additional $2.5 million from other warrant exercises. The warrants exercised had exercise prices ranging from $1.20 to $1.25 per share and the total number of shares of common stock issued upon exercises both in connection with the Warrant Exercise Inducement Offering and other warrant exercises was approximately 4.2 million shares. Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, cash received from the exercise of outstanding common stock warrants, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all. |
Sales of Equity Securities
Sales of Equity Securities | 6 Months Ended |
Jun. 30, 2019 | |
Equity [Abstract] | |
Sales of Equity Securities | 3. Sales of Equity Securities On January 30, 2018, the Company received net cash proceeds of approximately $13.3 million from the closing of a follow-on public offering of 1,095,153 shares of its common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit, with $1.4 million of costs directly associated with the offering recorded as an offset to additional paid-in capital under applicable accounting guidance. All warrants sold in this offering have an exercise price of $1.20 per share, which is subject to down round adjustment, are exercisable immediately and expire five years from the date of issuance. The aggregate estimated grant date fair value of $9.7 million was recorded as an offset to additional paid-in capital upon the closing of this offering (see Note 4). In May 2018, the SEC declared effective a shelf registration statement filed by the Company, which expires in May 2021. The shelf registration statement allows the Company to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million. On August 13, 2018, the Company completed a rights offering. Pursuant to the rights offering, the Company sold an aggregate of 11,587 units consisting of an aggregate of 11,587 shares of Series A Preferred Stock and 2,549,140 warrants, with each warrant exercisable for one share of our common stock at an exercise price of $4.53 per share, resulting in net proceeds to the Company of approximately $10.1 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. Each share of Series A Preferred Stock will be convertible, at the Company’s option at any time on or after the first anniversary of the closing of the Rights Offering or at the option of the holder at any time, into the number of shares of the Company’s common stock, par value $0.0001 per share determined by dividing the $1,000 stated value per share of the Series A Preferred Stock by a conversion price of $4.53 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Holders of Series A Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of Common Stock. The Series A Preferred Stock have no voting rights. Upon the Company’s liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series A Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted (disregarding for such purpose any conversion limitations thereunder) to Common Stock, which amounts shall be paid pari passu with all holders of Common Stock. The Company is not obligated to redeem or repurchase any shares of Series A Preferred Stock. On September 20, 2018, the Company completed an offering of 642,438 shares of the Company’s common stock and prefunded warrants to purchase up to an aggregate of 120,000 shares of its common stock. The shares were sold at a purchase price of $3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to the Company from this offering were approximately $2.2 million, after deducting expenses related to the offering including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering have an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date. On January 18, 2019, the Company completed an offering of 990,000 shares of the Company’s common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses. On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million as a result of the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 price per share offering price in the February 2019 financing transaction. On March 19, 2019, the Company received net cash proceeds of approximately $7.5 million as a result of completing a registered direct offering of 5,950,000 shares at a negotiated purchase price of $1.37 per share. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share purchased for cash in the offering. All warrants issued in this offering have an exercise price of $1.25 per share, are exercisable immediately upon issuance and expire 5.5 years following the date of issuance. In May 2019, the Company received cash proceeds of approximately $2.5 million from the exercise of 2,086,479 February 2019 warrants at $1.20 per share. On May 28, 2019, the Company entered into Warrant Exercise Agreements, or the Exercise Agreements, with certain of the holders of its existing warrants, or the Exercising Holders. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that, subject to any applicable beneficial ownership limitations, the Exercising Holders would cash exercise up to 20% of their Existing Warrants, or the Investor Warrants, into shares of Common Stock underlying such Existing Warrants, or the Exercised Shares. In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date. The New Warrants have an exercise price per share of $1.31. A total of 2,062,966 Investor Warrants were exercised contemporaneously with the execution of the Exercise Agreements resulting in total proceeds to the Company of $2.3 million, net of investment banking fees. The warrants issued in connection with the Exercise Agreement were considered inducement warrants and are classified in equity. The fair value of the warrants issued was approximately $1.8 million (see valuation assumptions in Note 4). The fair value of the inducement warrants of $1.8 million was expensed as warrant inducement expense in the accompanying consolidated statements of operations for the three and six months ended June 30, 2019. On July 15, 2019, the Company entered into amendments (the “Amendments”) to the Exercise Agreements. Pursuant to the Amendments, the period during which the Exercising Holders may elect to exercise for cash the Existing Warrants in exchange for new warrants to purchase Common Stock to be issued in an amount equal to 75% of the number of shares of Common Stock exercised under the Existing Warrants was extended from July 15, 2019 to July 31, 2019. There had been no additional warrants exercised under the Amendments as the date this Quarterly Report on 10-Q was filed. |
Fair Value Measurement
Fair Value Measurement | 6 Months Ended |
Jun. 30, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | 4. Fair Value Measurement The estimated nonrecurring fair value measurements associated with fixed asset purchases recorded as right-of-use asset finance lease obligations totaling approximately $149,000 during the six months ended June 30, 2019 were calculated as the present value of the lease payments based on contractual payment amounts and estimated market rates. Upon adoption of guidance in ASC Topic 842 Leases, the estimated fair value of the right-of-use operating lease asset was recorded based on present value of future lease payments based contractual payment amounts and estimated market rates in effect. Other Fair Value Measurements As of the closing of the Company’s January 30, 2018 offering, the grant date fair value of the warrants issued to purchase up to 1,095,153 shares of common stock was estimated to be approximately $8.82 per share, or a total of approximately $9.7 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering have an exercise price of $1.20 per share, which is subject to down round adjustment, and expire five years from the date of issuance. The fair value of the warrants was estimated using a Monte Carlo simulation valuation model using Geometric Brownian Motion, incorporating anticipated future financing events, with the following assumptions: Beginning stock price $ 10.17 Exercise price $ 15.00 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.48 % Expected life (in years) 5.00 Expected volatility 99.0 % As of the closing of the Company’s February 12, 2019 offering, the estimated grant date fair value of approximately $0.95 per share associated with the warrants to purchase up to 7,165,000 shares of common stock issued in this offering, or a total of approximately $6.8 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.05 Exercise price $ 1.20 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.49 % Expected life (in years) 5.00 Expected volatility 147.7 % As of the closing of the Company’s March 19, 2019 offering, the estimated grant date fair value of approximately $1.01 per share associated with the warrants to purchase up to 5,950,000 shares of common stock issued in this offering, or a total of approximately $6.0 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.25 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.12 Exercise price $ 1.25 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.44 % Expected life (in years) 5.50 Expected volatility 140.0 % As of the closing of the Company’s May 30, 2019 warrant inducement transaction, the estimated grant date fair value of approximately $1.18 per share associated with the warrants to purchase up to 1,547,226 shares of common stock issued in this offering, or a total of approximately $1.8 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. All warrants issued in this warrant inducement transaction have an exercise price of $1.31 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 1.29 Exercise price $ 1.31 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.05 % Expected life (in years) 5.50 Expected volatility 145.9 % |
Balance Sheet Details
Balance Sheet Details | 6 Months Ended |
Jun. 30, 2019 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Balance Sheet Details | 5. Balance Sheet Details The following provides certain balance sheet details: December 31, June 30, 2018 2019 Fixed Assets Machinery and equipment $ 2,818,583 $ 2,823,938 Furniture and office equipment 157,391 157,391 Computer equipment and software 1,437,408 1,552,891 Leasehold improvements 570,173 570,174 Financed equipment 2,573,955 — Construction in process 116,640 134,859 Total fixed assets, gross 7,674,150 5,239,253 Less accumulated depreciation and amortization (4,934,728 ) (4,020,150 ) Total fixed assets, net $ 2,739,422 $ 1,219,103 Accrued Liabilities Accrued payroll $ 255,426 $ 194,917 Accrued vacation 535,682 573,655 Accrued bonuses 712,574 447,432 Accrued sales commissions 62,767 87,224 Current portion of deferred rent 158,342 — Accrued other 203,602 187,580 Total accrued liabilities $ 1,928,393 $ 1,490,808 During the six months ended June 30, 2019 there were no disposals and $139,000 of fixed assets were acquired. Upon adoption of the lease guidance in ASC Topic 842, Leases (ASC 842), equipment with a total cost of $2,574,000 and accumulated depreciation of $1,135,000 were reclassified to leases right-of-use assets on the Company’s balance sheet (see Note 7). Depreciation expense for the six months ended June 30, 2018 was $357,173 and for the six months ended June 30, 2019 was $450,984. Depreciation expense for the three months ended June 30, 2018 was $177,401 and for the three months ended June 30, 2019 was $228,856. |
April 2014 Credit Facility
April 2014 Credit Facility | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
April 2014 Credit Facility | 6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility. Upon entering into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility was secured by substantially all of the Company’s personal property other than its intellectual property. The term loan under the April 2014 Credit Facility bore interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matured on July 1, 2018. Under the original terms of the underlying agreement, the Company was also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. Upon maturity of the April 2014 Credit Facility on July 1, 2018, security interest in the Company’s personal property was released by the lender. A warrant to purchase up to 588 shares of the Company’s common stock at an exercise price of $424.80 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of approximately $102,000 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of approximately $4,898,000. The estimated fair value of the warrant issued of approximately $233,000 was also recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs were amortized to interest expense utilizing the effective interest method over the underlying term of the loan. |
Leases
Leases | 6 Months Ended |
Jun. 30, 2019 | |
Leases [Abstract] | |
Leases | 7. Leases Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method. The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases. Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet. In addition, assets under equipment leases previously classified as capital leases within Property, Plant and Equipment on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance. Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term. As the Company’s operating lease does not provide an implicit rate, an estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Finance Leases The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight line basis over the lease term. Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance. The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 3 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $2,574,000 and $2,723,000 at December 31, 2018 and June 30, 2019, respectively. Total accumulated depreciation related to equipment under finance leases was approximately $1,135,000 and $1,366,000 at December 31, 2018 and June 30, 2019, respectively. Total depreciation expense related to equipment under finance leases during the three months ended June 30, 2018 and 2019 was approximately $89,000, and was approximately $156,000 and $231,000 during the six months ended June 30, 2018 and 2019, respectively. On January 31, 2019, the Company executed an equipment financing commitment with a third-party lender for total proceeds of approximately $149,000, which was funded by the lender on February 1, 2019. Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full after 36 monthly installments of $5,013 totaling approximately $180,000 through February 2022. Operating Lease The Company leases its primary laboratory and office facilities in San Diego, California. This lease is classified as an operating lease in accordance with the ASC 842 guidance. The average monthly cash payment for the operating lease is approximately $120,000 per month, and the lease term ends on July 31, 2020. The Company recorded a lease right-of-use asset and lease liability of $1,930,000 and $2,201,000, respectively, as of January 1, 2019, based on present value of payments and an incremental borrowing rate of 4.5%. In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments. The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and June 30, 2019 as follows: December 31, June 30, 2018 2019 Lease right-of-use assets: Operating $ — $ 1,337,240 Finance — 1,357,206 Total $ — $ 2,694,446 The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and June 30, 2019: December 31, June 30, 2018 2019 Current portion of lease liabilities: Operating $ — $ 1,411,385 Finance — 635,028 Total $ — $ 2,046,413 The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and June 30, 2019: December 31, June 30, 2018 2019 Long-term portion of lease liability: Operating $ — $ 121,706 Finance — 861,713 Total $ — $ 983,419 The following schedule represents the components of lease expense for the three and six months ended June 30, 2019 and 2018: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Lease costs Finance lease cost Amortization of right-of-use assets — $ 119,599 — $ 229,929 Interest on lease liabilities — 63,574 — 125,548 Operating lease cost — 318,005 — 636,010 Total $ — $ 501,178 $ — $ 991,487 The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of June 30, 2019: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2019 $ 351,616 $ 46,833 $ 718,740 2020 611,772 77,298 855,136 2021 365,168 56,136 — 2022 268,056 62,778 — Thereafter 286,746 45,710 — Total payments 1,883,358 288,755 1,573,876 Less amount representing interest (388,607 ) — (40,785 ) Present value of payments $ 1,494,751 $ 288,755 $ 1,533,091 The following schedule sets forth supplemental cash flow information related to operating and finance leases as of June 30, 2019: For the six months ended June 30, 2019 Other information Operating cash flows from finance leases $ 125,548 Operating cash flows from operating leases $ 711,624 Financing cash flows from finance leases $ 277,250 The aggregate weighted average remaining lease term was 3.19 years on finance leases and 1.09 years on operating leases as of June 30, 2019. The aggregate weighted average discount rate was 21.17% on finance leases and 4.5% on operating leases as of June 30, 2019. During the six months ended June 30, 2019, the Company added $149,000 of right of use assets in exchange for finance lease liabilities. In addition, upon adoption of the accounting guidance in ASC 842, $1.4 million of net machinery and equipment was reclassified to lease right-of-use assets related to assets under finance leases and $1.9 million of right-of-use facility lease was recorded under operating lease. |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Jun. 30, 2019 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock-Based Compensation | 8. Stock-Based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. At the Company’s annual meeting of stockholders held on June 28, 2018, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 146,666 shares. At the Company’s annual meeting of stockholders held on June 17, 2019, the Company’s stockholders approved additional amendments to the 2013 Plan including the increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 2,800,000 shares. As of June 30, 2019, 124,211 shares of the Company’s common stock were authorized exclusively for the issuance of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. As of June 30, 2019, under all plans, a total of 3,064,098 non-inducement shares were authorized for issuance, 2,681,587 shares had been issued with 2,650,970 non-inducement stock options and restricted stock units, or RSUs, underlying outstanding awards, and 382,511 non-inducement shares were available for grant. As of June 30, 2019, 118,368 inducement shares were authorized for issuance, 118,368 inducement shares had been issued under the 2013 Plan, with 117,534 inducement stock options and RSUs underlying outstanding awards and no inducement shares available for grant. Stock Options A summary of stock option activity for the six months ended June 30, 2019 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2018 195,820 $ 41.41 9.20 Granted 2,586,329 $ 0.91 Exercised — — Cancelled/forfeited/expired (13,706 ) $ 21.04 Outstanding at June 30, 2019 2,768,443 $ 3.67 9.76 Vested and unvested expected to vest at June 30, 2019 2,652,838 $ 3.78 9.76 The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2018 and June 30, 2019 were each approximately zero. The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2019 were as follows: Stock and exercise prices $0.91 - $1.03 Expected dividend yield 0.00% Discount rate-bond equivalent yield 1.76% – 2.55% Expected life (in years) 5.0 – 5.96 Expected volatility 128% - 156% On April 30, 2019, the Company’s Board of Directors approved the issuance of an aggregate of 2,578,229 options to be granted to the Company’s employees, executives and Board members pursuant to the 2013 Amended Plan, subject to shareholder approval of the increase of the options available under the 2013 Amended Plan at the Company’s annual meeting on June 17, 2019. On June 17, 2019 the Company’s shareholders approved the increase to the 2013 Amended Plan by 2.8 million shares. Restricted Stock A summary of RSU activity for the six months ended June 30, 2019 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2018 360 $ 415.80 Granted — — Vested and issued — — Forfeited — — Outstanding at June 30, 2019 360 $ 415.80 Vested and unvested expected to vest at June 30, 2019 360 $ 415.80 At June 30, 2019, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were each approximately $400. Of the 360 RSUs outstanding at June 30, 2019, all were fully vested. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2018 2019 2018 2019 Stock Options Cost of revenues $ 9,421 $ 17,073 $ 27,000 $ 25,220 Research and development expenses 35,873 36,922 73,020 65,116 General and administrative expenses 81,284 145,037 186,458 192,618 Sales and marketing expenses 24,788 25,609 48,054 44,146 Total expenses related to stock options 151,366 224,641 334,532 327,100 RSUs Cost of revenues (1,552 ) — (18,802 ) — Research and development expenses 3,561 — 13,576 — General and administrative expenses 14,243 — 54,303 — Sales and marketing expenses 6,076 — 15,348 — Total stock-based compensation $ 173,694 $ 224,641 $ 398,957 $ 327,100 Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during each of the three and six-months ended June 30, 2018 and 2019. As of June 30, 2019, total unrecognized share-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,627,000 and is expected to be recognized over a weighted-average period of approximately 3.3 years. |
Common Stock Warrants Outstandi
Common Stock Warrants Outstanding | 6 Months Ended |
Jun. 30, 2019 | |
Other Liabilities Disclosure [Abstract] | |
Common Stock Warrants Outstanding | 9. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the six months ended June 30, 2019 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2018 4,694,927 $ 8.55 4.4 Issued 14,662,226 1.23 Exercised (4,155,430 ) 1.20 Expired (4,474 ) 953.06 Outstanding at June 30, 2019 15,197,249 $ 3.08 4.7 Further information about equity-classified common stock warrants outstanding at June 30, 2019 is as follows: Weighted Weighted Average Average Total Shares Contractual Exercise Price Outstanding Life (in years) $ 1.24 11,601,949 4.9 $ 4.21 3,311,578 4.2 $ 25.50 8,208 3.4 $ 33.00 96,999 2.3 $ 45.00 47,821 3.1 $ 75.00 71,995 3.3 $ 117.00 38,772 1.8 $ 140.40 19,339 0.6 $ 424.80 588 4.8 15,197,249 All warrants outstanding at June 30, 2019 are exercisable. The intrinsic value of equity-classified common stock warrants outstanding at June 30, 2019 was zero. |
Net Loss per Common Share
Net Loss per Common Share | 6 Months Ended |
Jun. 30, 2019 | |
Earnings Per Share [Abstract] | |
Net Loss per Common Share | 10. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and six-months ended June 30, 2018 and 2019, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the six months ended June 30, 2018 2019 Preferred warrants outstanding (number of common stock equivalents) 17 17 Common warrants outstanding 1,383,349 15,197,249 RSUs outstanding 360 360 Convertible preferred stock outstanding (number of common stock equivalents) — 471,393 Common options outstanding 62,264 2,768,443 Total anti-dilutive common share equivalents 1,445,990 18,437,462 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2019 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 11. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020. At June 30, 2019, a balance of approximately $216,000 remained outstanding under this purchase commitment. During the three months ended June 30, 2018 and 2019, total expense recorded in the Company’s unaudited condensed statements of operations and comprehensive loss for sales tax and maintenance obligations associated with equipment financing arrangements was approximately $27,000 and $23,000, respectively, with approximately $50,000 and $47,000 recorded during the six months ended June 30, 2018 and 2019, respectively. At December 31, 2018 and June 30, 2019, approximately $69,000 and $70,000, respectively, of such sales tax and maintenance obligations incurred but not paid were recorded in accrued other liabilities in the Company’s balance sheet (see Note 5). Future amounts totaling approximately $288,755 for sales tax and maintenance obligations associated with financed equipment were due under equipment financing arrangements at June 30, 2019, which will be expensed as incurred (see Note 7). |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 12. Related Party Transactions A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of approximately $26,000 in April 2019 from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | 13. Subsequent Events In July 2019, the Company entered into amendments, or the Warrant Exercise Agreement Amendments, to the Exercise Agreements the Company previously entered into in May 2019 with the Exercising Holders . |
The Company, Business Activit_2
The Company, Business Activities and Basis of Presentation (Policies) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
The Company and Business Activities | The Company and Business Activities The Company was founded in California in May 1997 and effected a reincorporation to Delaware in July 2013. The Company is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC TM Further, sales to laboratory supply distributors of our proprietary blood collection tubes, or BCTs, commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. As such, all references to share and per share amounts in these unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the one-for-thirty reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 29, 2019 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss. |
Revenue Recognition and Accounts Receivable | Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Contracts For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and six months ended June 30, 2018 and 2019. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three and six-months ended June 30, 2018 and 2019, disaggregated by source and nature, are as follows: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Net revenues from contracted payers* $ 356,000 $ 489,901 $ 694,760 $ 971,320 Net revenues from non-contracted payers 414,742 628,477 828,851 1,125,847 Development services revenues 51,496 45,081 96,130 87,579 Kits and Blood Collection Tubes (BCT) — 27,864 9,440 30,816 Total net revenues $ 822,238 $ 1,191,323 $ 1,629,181 $ 2,215,562 *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Net commercial revenues recognized upon delivery $ 770,742 $ 1,118,378 $ 1,523,611 $ 2,009,364 Development services revenues recognized upon delivery 51,496 45,081 96,130 87,579 Commercial revenues recognized upon cash collection — — — 87,803 Kits and Blood Collection Tubes (BCT) — 27,864 9,440 30,816 Total net revenues $ 822,238 $ 1,191,323 $ 1,629,181 $ 2,215,562 Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2018 and 2019 were as follows: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Medicare and Medicare Advantage 38 % 43 % 39 % 45 % Blue Cross Blue Shield 12 % 20 % 17 % 17 % United Healthcare 15 % 8 % 19 % 10 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and June 30, 2019 were as follows: December 31, 2018 June 30, 2019 Blue Cross Blue Shield 22 % 23 % Medicare and Medicare Advantage 17 % 18 % United Healthcare 15 % 15 % |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In February 2016, the FASB issued authoritative guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months be recognized on the balance sheet. The guidance is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2018. Effective January 1, 2019, the Company adopted the guidance and elected the optional transition method to account for the impact of the adoption with a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company also elected the practical expedient package as permitted under the transition guidance. As of January 1, 2019, the Company recorded a right-of-use asset and liability upon adoption of the guidance (See Note 7). In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity. In February 2018, the FASB issued authoritative guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from a tax bill, “H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018,” or the Tax Cuts and Jobs Act, enacted on December 22, 2017. These amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act. However, because these amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This guidance also requires certain disclosures about stranded tax effects. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 which did not have a material impact on its financial statements or disclosures because the Company does not currently maintain any stranded tax effects in accumulated other comprehensive income. In June 2018, the FASB issued authoritative guidance simplifying the accounting for nonemployee stock-based compensation and largely aligning such compensation with the accounting requirements for employee stock-based awards. For public companies, this guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures. In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606). The Company currently intends to adopt this guidance upon the effective date and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures. |
The Company, Business Activit_3
The Company, Business Activities and Basis of Presentation (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Composition of Net Revenues Recognized Disaggregated by Source and Nature | The composition of the Company’s net revenues recognized during the three and six-months ended June 30, 2018 and 2019, disaggregated by source and nature, are as follows: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Net revenues from contracted payers* $ 356,000 $ 489,901 $ 694,760 $ 971,320 Net revenues from non-contracted payers 414,742 628,477 828,851 1,125,847 Development services revenues 51,496 45,081 96,130 87,579 Kits and Blood Collection Tubes (BCT) — 27,864 9,440 30,816 Total net revenues $ 822,238 $ 1,191,323 $ 1,629,181 $ 2,215,562 *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Net commercial revenues recognized upon delivery $ 770,742 $ 1,118,378 $ 1,523,611 $ 2,009,364 Development services revenues recognized upon delivery 51,496 45,081 96,130 87,579 Commercial revenues recognized upon cash collection — — — 87,803 Kits and Blood Collection Tubes (BCT) — 27,864 9,440 30,816 Total net revenues $ 822,238 $ 1,191,323 $ 1,629,181 $ 2,215,562 |
Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage | The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and six-months ended June 30, 2018 and 2019 were as follows: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Medicare and Medicare Advantage 38 % 43 % 39 % 45 % Blue Cross Blue Shield 12 % 20 % 17 % 17 % United Healthcare 15 % 8 % 19 % 10 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and June 30, 2019 were as follows: December 31, 2018 June 30, 2019 Blue Cross Blue Shield 22 % 23 % Medicare and Medicare Advantage 17 % 18 % United Healthcare 15 % 15 % |
Fair Value Measurement (Tables)
Fair Value Measurement (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Fair Value Disclosures [Abstract] | |
Assumptions Used for Determining Fair Values of Common Stock Warrants | The fair value of the warrants was estimated using a Monte Carlo simulation valuation model using Geometric Brownian Motion, incorporating anticipated future financing events, with the following assumptions: Beginning stock price $ 10.17 Exercise price $ 15.00 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.48 % Expected life (in years) 5.00 Expected volatility 99.0 % Beginning stock price $ 1.05 Exercise price $ 1.20 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.49 % Expected life (in years) 5.00 Expected volatility 147.7 % Beginning stock price $ 1.12 Exercise price $ 1.25 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.44 % Expected life (in years) 5.50 Expected volatility 140.0 % Beginning stock price $ 1.29 Exercise price $ 1.31 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 2.05 % Expected life (in years) 5.50 Expected volatility 145.9 % |
Balance Sheet Details (Tables)
Balance Sheet Details (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Schedule of Fixed Assets and Accrued Liabilities | The following provides certain balance sheet details: December 31, June 30, 2018 2019 Fixed Assets Machinery and equipment $ 2,818,583 $ 2,823,938 Furniture and office equipment 157,391 157,391 Computer equipment and software 1,437,408 1,552,891 Leasehold improvements 570,173 570,174 Financed equipment 2,573,955 — Construction in process 116,640 134,859 Total fixed assets, gross 7,674,150 5,239,253 Less accumulated depreciation and amortization (4,934,728 ) (4,020,150 ) Total fixed assets, net $ 2,739,422 $ 1,219,103 Accrued Liabilities Accrued payroll $ 255,426 $ 194,917 Accrued vacation 535,682 573,655 Accrued bonuses 712,574 447,432 Accrued sales commissions 62,767 87,224 Current portion of deferred rent 158,342 — Accrued other 203,602 187,580 Total accrued liabilities $ 1,928,393 $ 1,490,808 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Leases [Abstract] | |
Schedule of Right-Of-Use Lease Assets | The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and June 30, 2019 as follows: December 31, June 30, 2018 2019 Lease right-of-use assets: Operating $ — $ 1,337,240 Finance — 1,357,206 Total $ — $ 2,694,446 |
Schedule of Current Portion of Operating and Finance Lease Liabilities | The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and June 30, 2019: December 31, June 30, 2018 2019 Current portion of lease liabilities: Operating $ — $ 1,411,385 Finance — 635,028 Total $ — $ 2,046,413 |
Schedule of Long-Term Portion of Operating and Finance Lease Liabilities | The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and June 30, 2019: December 31, June 30, 2018 2019 Long-term portion of lease liability: Operating $ — $ 121,706 Finance — 861,713 Total $ — $ 983,419 |
Schedule of Lease Expenses | The following schedule represents the components of lease expense for the three and six months ended June 30, 2019 and 2018: For the three months ended June 30, For the six months ended June 30, 2018 2019 2018 2019 Lease costs Finance lease cost Amortization of right-of-use assets — $ 119,599 — $ 229,929 Interest on lease liabilities — 63,574 — 125,548 Operating lease cost — 318,005 — 636,010 Total $ — $ 501,178 $ — $ 991,487 |
Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases | The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of June 30, 2019: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2019 $ 351,616 $ 46,833 $ 718,740 2020 611,772 77,298 855,136 2021 365,168 56,136 — 2022 268,056 62,778 — Thereafter 286,746 45,710 — Total payments 1,883,358 288,755 1,573,876 Less amount representing interest (388,607 ) — (40,785 ) Present value of payments $ 1,494,751 $ 288,755 $ 1,533,091 |
Supplemental Cash Flow Information Related to Operating and Finance Leases | The following schedule sets forth supplemental cash flow information related to operating and finance leases as of June 30, 2019: For the six months ended June 30, 2019 Other information Operating cash flows from finance leases $ 125,548 Operating cash flows from operating leases $ 711,624 Financing cash flows from finance leases $ 277,250 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Summary of Stock Option Activity | A summary of stock option activity for the six months ended June 30, 2019 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2018 195,820 $ 41.41 9.20 Granted 2,586,329 $ 0.91 Exercised — — Cancelled/forfeited/expired (13,706 ) $ 21.04 Outstanding at June 30, 2019 2,768,443 $ 3.67 9.76 Vested and unvested expected to vest at June 30, 2019 2,652,838 $ 3.78 9.76 |
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model | The assumptions used in the Black-Scholes pricing model for stock options granted during the six months ended June 30, 2019 were as follows: Stock and exercise prices $0.91 - $1.03 Expected dividend yield 0.00% Discount rate-bond equivalent yield 1.76% – 2.55% Expected life (in years) 5.0 – 5.96 Expected volatility 128% - 156% |
Summary of RSU Activity | A summary of RSU activity for the six months ended June 30, 2019 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2018 360 $ 415.80 Granted — — Vested and issued — — Forfeited — — Outstanding at June 30, 2019 360 $ 415.80 Vested and unvested expected to vest at June 30, 2019 360 $ 415.80 |
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss | The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2018 2019 2018 2019 Stock Options Cost of revenues $ 9,421 $ 17,073 $ 27,000 $ 25,220 Research and development expenses 35,873 36,922 73,020 65,116 General and administrative expenses 81,284 145,037 186,458 192,618 Sales and marketing expenses 24,788 25,609 48,054 44,146 Total expenses related to stock options 151,366 224,641 334,532 327,100 RSUs Cost of revenues (1,552 ) — (18,802 ) — Research and development expenses 3,561 — 13,576 — General and administrative expenses 14,243 — 54,303 — Sales and marketing expenses 6,076 — 15,348 — Total stock-based compensation $ 173,694 $ 224,641 $ 398,957 $ 327,100 |
Common Stock Warrants Outstan_2
Common Stock Warrants Outstanding (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Equity Classified Warrants [Abstract] | |
Summary of Equity-Classified Common Stock Warrant Activity | A summary of equity-classified common stock warrant activity for the six months ended June 30, 2019 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2018 4,694,927 $ 8.55 4.4 Issued 14,662,226 1.23 Exercised (4,155,430 ) 1.20 Expired (4,474 ) 953.06 Outstanding at June 30, 2019 15,197,249 $ 3.08 4.7 |
Schedule of Equity-Classified Common Stock Warrants, Outstanding | Further information about equity-classified common stock warrants outstanding at June 30, 2019 is as follows: Weighted Weighted Average Average Total Shares Contractual Exercise Price Outstanding Life (in years) $ 1.24 11,601,949 4.9 $ 4.21 3,311,578 4.2 $ 25.50 8,208 3.4 $ 33.00 96,999 2.3 $ 45.00 47,821 3.1 $ 75.00 71,995 3.3 $ 117.00 38,772 1.8 $ 140.40 19,339 0.6 $ 424.80 588 4.8 15,197,249 |
Net Loss per Common Share (Tabl
Net Loss per Common Share (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Earnings Per Share [Abstract] | |
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares | The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the six months ended June 30, 2018 2019 Preferred warrants outstanding (number of common stock equivalents) 17 17 Common warrants outstanding 1,383,349 15,197,249 RSUs outstanding 360 360 Convertible preferred stock outstanding (number of common stock equivalents) — 471,393 Common options outstanding 62,264 2,768,443 Total anti-dilutive common share equivalents 1,445,990 18,437,462 |
The Company, Business Activit_4
The Company, Business Activities and Basis of Presentation - Additional Information (Detail) | Jul. 06, 2018shares | Jun. 30, 2019shares | Dec. 31, 2018shares |
The Company Business Activities And Basis Of Presentation [Line Items] | |||
Stockholders equity reverse stock split ratio | 0.03 | ||
Common stock, shares authorized | 150,000,000 | 150,000,000 | 150,000,000 |
Description of reverse stock split | On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. | ||
ASC 606 [Member] | |||
The Company Business Activities And Basis Of Presentation [Line Items] | |||
Performance obligation, description of timing | The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. | ||
Practical expedient, description | The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. | ||
ASC 606 [Member] | Maximum [Member] | Sales and Marketing Expenses [Member] | |||
The Company Business Activities And Basis Of Presentation [Line Items] | |||
Amortization period | 1 year |
The Company, Business Activit_5
The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | ||
Disaggregation Of Revenue [Line Items] | |||||
Total net revenues | $ 1,191,323 | $ 822,238 | $ 2,215,562 | $ 1,629,181 | |
Commercial Revenues [Member] | Contracted Payers [Member] | |||||
Disaggregation Of Revenue [Line Items] | |||||
Total net revenues | [1] | 489,901 | 356,000 | 971,320 | 694,760 |
Commercial Revenues [Member] | Non-Contracted Payers [Member] | |||||
Disaggregation Of Revenue [Line Items] | |||||
Total net revenues | 628,477 | 414,742 | 1,125,847 | 828,851 | |
Development Services Revenues [Member] | |||||
Disaggregation Of Revenue [Line Items] | |||||
Total net revenues | 45,081 | $ 51,496 | 87,579 | 96,130 | |
Kits and Blood Collection Tubes [Member] | |||||
Disaggregation Of Revenue [Line Items] | |||||
Total net revenues | $ 27,864 | $ 30,816 | $ 9,440 | ||
[1] | Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed. |
The Company, Business Activit_6
The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
The Company Business Activities And Basis Of Presentation [Line Items] | ||||
Total net revenues | $ 1,191,323 | $ 822,238 | $ 2,215,562 | $ 1,629,181 |
Commercial Revenues [Member] | Net Commercial Revenues Recognized Upon Delivery [Member] | ||||
The Company Business Activities And Basis Of Presentation [Line Items] | ||||
Total net revenues | 1,118,378 | 770,742 | 2,009,364 | 1,523,611 |
Commercial Revenues [Member] | Commercial Revenues Recognized Upon Cash Collection [Member] | ||||
The Company Business Activities And Basis Of Presentation [Line Items] | ||||
Total net revenues | 87,803 | |||
Development Services Revenues [Member] | ||||
The Company Business Activities And Basis Of Presentation [Line Items] | ||||
Total net revenues | 45,081 | $ 51,496 | 87,579 | 96,130 |
Kits and Blood Collection Tubes [Member] | ||||
The Company Business Activities And Basis Of Presentation [Line Items] | ||||
Total net revenues | $ 27,864 | $ 30,816 | $ 9,440 |
The Company, Business Activit_7
The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Customer Concentration Risk [Member] | Net Revenues [Member] | Blue Cross Blue Shield [Member] | |||||
Concentration Risk [Line Items] | |||||
Concentration risk percentage | 20.00% | 12.00% | 17.00% | 17.00% | |
Customer Concentration Risk [Member] | Net Revenues [Member] | Medicare and Medicare Advantage [Member] | |||||
Concentration Risk [Line Items] | |||||
Concentration risk percentage | 43.00% | 38.00% | 45.00% | 39.00% | |
Customer Concentration Risk [Member] | Net Revenues [Member] | United Healthcare [Member] | |||||
Concentration Risk [Line Items] | |||||
Concentration risk percentage | 8.00% | 15.00% | 10.00% | 19.00% | |
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Blue Cross Blue Shield [Member] | |||||
Concentration Risk [Line Items] | |||||
Concentration risk percentage | 23.00% | 22.00% | |||
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Medicare and Medicare Advantage [Member] | |||||
Concentration Risk [Line Items] | |||||
Concentration risk percentage | 18.00% | 17.00% | |||
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | United Healthcare [Member] | |||||
Concentration Risk [Line Items] | |||||
Concentration risk percentage | 15.00% | 15.00% |
Liquidity and Going Concern U_2
Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($) | Mar. 19, 2019 | Mar. 11, 2019 | Feb. 12, 2019 | Jan. 18, 2019 | Sep. 20, 2018 | Aug. 13, 2018 | Jan. 30, 2018 | May 31, 2019 | May 31, 2018 | Feb. 29, 2016 | May 31, 2015 | Jun. 30, 2019 | Mar. 31, 2019 | Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Feb. 28, 2019 | Dec. 31, 2017 |
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Cash | $ 12,590,597 | $ 2,569,111 | $ 12,590,597 | $ 2,569,111 | $ 3,423,373 | $ 2,146,611 | ||||||||||||||
Accumulated deficit | (234,290,120) | (234,290,120) | (220,457,578) | |||||||||||||||||
Net loss | (7,816,012) | $ (5,916,787) | $ (6,153,101) | $ (6,357,143) | (13,732,799) | (12,510,244) | $ (24,600,000) | |||||||||||||
Aggregate net interest-bearing indebtedness | 1,800,000 | 1,800,000 | ||||||||||||||||||
Aggregate net interest-bearing indebtedness due within one year | 899,000 | 899,000 | ||||||||||||||||||
Other non-interest bearing current liabilities | 3,500,000 | 3,500,000 | ||||||||||||||||||
Unconditional purchase commitment aggregate amount | $ 1,062,500 | $ 216,000 | $ 216,000 | |||||||||||||||||
Unconditional purchase commitment payment terms | Quarterly | |||||||||||||||||||
Unconditional purchase commitment period | May 31, 2020 | |||||||||||||||||||
Proceeds from issuance of common stock, net of issuance costs | $ 7,500,000 | $ 2,000,000 | ||||||||||||||||||
Proceeds from exercise of common stock warrants | $ 4,800,000 | $ 2,513,172 | $ 0 | |||||||||||||||||
Public offering, number of common stock and warrants issued | 642,438 | |||||||||||||||||||
Stock price | $ 1.37 | $ 2.25 | $ 3.285 | |||||||||||||||||
Exercise price of unregistered warrants | $ 1.25 | $ 1.20 | $ 4.53 | $ 1.20 | $ 1.20 | |||||||||||||||
Aggregate units sold under right offering | 11,587 | |||||||||||||||||||
Shares issued in offering | 5,950,000 | 990,000 | ||||||||||||||||||
Warrant exercisable for share of common stock | 1 | 1 | ||||||||||||||||||
Net proceeds from issuance of units, net of issuance expenses | $ 2,200,000 | $ 10,100,000 | ||||||||||||||||||
Class of warrant or rights, term | 5 years 6 months | 5 years | ||||||||||||||||||
Proceeds from warrant exercise inducement, net | $ 2,337,298 | |||||||||||||||||||
Prefunded Warrants [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Exercise price of unregistered warrants | $ 3.275 | |||||||||||||||||||
Change in exercise price of warrants | 0.01 | |||||||||||||||||||
May 2019 Warrant Exercise Inducement Offering [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Proceeds from warrant exercise inducement, net | 2,300,000 | |||||||||||||||||||
Other Warrant Exercises [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Proceeds from exercise of common stock warrants | 2,500,000 | |||||||||||||||||||
Warrant [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Proceeds from exercise of common stock warrants | $ 2,500,000 | |||||||||||||||||||
Aggregate warrants sold under right offering | 2,549,140 | |||||||||||||||||||
Common Stock [Member] | Warrant Exercise Inducement Offering and Other Warrant Exercises [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 4,200,000 | |||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Shares issued in offering | 11,587 | |||||||||||||||||||
Follow-on Public Offering [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Proceeds from issuance of common stock, net of issuance costs | $ 592,000 | $ 6,600,000 | $ 13,300,000 | |||||||||||||||||
Proceeds from exercise of common stock warrants | $ 0 | 0 | ||||||||||||||||||
Proceeds from gross exercise of common stock warrants outstanding | $ 1,300,000 | |||||||||||||||||||
Exercisable warrant available price per share | $ 1.20 | |||||||||||||||||||
Exercisable warrant available price per share expiration period | 2023-01 | |||||||||||||||||||
Public offering, number of common stock and warrants issued | 1,095,153 | |||||||||||||||||||
Stock price | $ 1.20 | $ 1.20 | $ 13.50 | |||||||||||||||||
Exercise price of unregistered warrants | $ 1.25 | $ 1.20 | $ 1.20 | |||||||||||||||||
Shares issued in offering | 6,250,000 | |||||||||||||||||||
Class of warrant or rights, term | 5 years 6 months | 5 years | 5 years | |||||||||||||||||
Purchase of common stock by underwriters to cover overallotments, number of shares | 538,867 | |||||||||||||||||||
Shelf Registration Statement [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Shelf registration statement expiration period | May 31, 2021 | May 31, 2021 | ||||||||||||||||||
Minimum public float limit for offering | $ 75,000,000 | $ 75,000,000 | ||||||||||||||||||
Private Placement [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Exercise price of unregistered warrants | $ 3.16 | |||||||||||||||||||
Warrant exercisable for share of common stock | 1 | |||||||||||||||||||
Class of warrant or rights, term | 5 years | |||||||||||||||||||
Over-allotment Option [Member] | Warrant [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Shares issued in offering | 915,000 | |||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Unconditional purchase commitment, quarterly payment amount | $ 62,500 | |||||||||||||||||||
Exercise price of unregistered warrants | $ 1.25 | |||||||||||||||||||
Minimum [Member] | Warrant Exercise Inducement Offering and Other Warrant Exercises [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Exercise price of unregistered warrants | 1.20 | |||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Exercise price of unregistered warrants | 1.20 | |||||||||||||||||||
Maximum [Member] | Prefunded Warrants [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 120,000 | |||||||||||||||||||
Maximum [Member] | Warrant Exercise Inducement Offering and Other Warrant Exercises [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Exercise price of unregistered warrants | $ 1.25 | |||||||||||||||||||
Maximum [Member] | Follow-on Public Offering [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 6,250,000 | 1,095,153 | ||||||||||||||||||
Maximum [Member] | Shelf Registration Statement [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Aggregate offering price | $ 50,000,000 | $ 50,000,000 | ||||||||||||||||||
Maximum [Member] | Over-allotment Option [Member] | ||||||||||||||||||||
Liquidity And Managements Plans [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 937,500 |
Sales of Equity Securities - Ad
Sales of Equity Securities - Additional Information (Detail) - USD ($) | Aug. 07, 2019 | Jul. 15, 2019 | May 30, 2019 | May 28, 2019 | Mar. 19, 2019 | Mar. 11, 2019 | Feb. 12, 2019 | Jan. 18, 2019 | Sep. 20, 2018 | Aug. 13, 2018 | Jan. 30, 2018 | Jul. 31, 2019 | May 31, 2019 | May 31, 2018 | May 31, 2015 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Feb. 28, 2019 | Dec. 31, 2018 |
Class Of Stock [Line Items] | ||||||||||||||||||||
Net cash proceeds from sale of securities | $ 7,500,000 | $ 2,000,000 | ||||||||||||||||||
Stock price | $ 1.37 | $ 2.25 | $ 3.285 | |||||||||||||||||
Exercise price of warrants | $ 1.25 | $ 1.20 | $ 4.53 | $ 1.20 | $ 1.20 | |||||||||||||||
Class of warrant or rights, term | 5 years 6 months | 5 years | ||||||||||||||||||
Issuance of warrants to purchase shares of common stock, grant date fair value | $ 1,800,000 | $ 6,000,000 | $ 6,800,000 | $ 9,700,000 | ||||||||||||||||
Aggregate units sold under right offering | 11,587 | |||||||||||||||||||
Public offering, number of shares issued | 5,950,000 | 990,000 | ||||||||||||||||||
Warrant exercisable for share of common stock | 1 | 1 | ||||||||||||||||||
Series A Preferred Stock convertible to common stock, conversion price | $ 4.53 | |||||||||||||||||||
Net proceeds from issuance of units, net of issuance expenses | $ 2,200,000 | $ 10,100,000 | ||||||||||||||||||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||||||||||
Public offering, number of common stock and warrants issued | 642,438 | |||||||||||||||||||
Proceeds from exercise of common stock warrants | $ 4,800,000 | $ 2,513,172 | $ 0 | |||||||||||||||||
Warrant inducement expense | $ 1,800,000 | $ 1,800,000 | ||||||||||||||||||
Prefunded Warrants [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Exercise price of warrants | $ 3.275 | |||||||||||||||||||
Change in exercise price of warrants | $ 0.01 | |||||||||||||||||||
Investor Warrants [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Exercise price of warrants | $ 1.31 | |||||||||||||||||||
Proceeds from exercise of common stock warrants | $ 2,300,000 | |||||||||||||||||||
Number of warrant exercised | 2,062,966 | |||||||||||||||||||
Cash exercise of warrants description | In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date. | |||||||||||||||||||
Fair value of warrants issued | $ 1,800,000 | |||||||||||||||||||
Warrants exercisable date | Jul. 15, 2019 | |||||||||||||||||||
Investor Warrants [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Number of warrant exercised | 0 | |||||||||||||||||||
Percentage of common stock exercised for exchange of new warrants | 75.00% | 75.00% | ||||||||||||||||||
Warrants exercisable date | Jul. 31, 2019 | Jul. 31, 2019 | ||||||||||||||||||
Warrant [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Aggregate warrants sold under right offering | 2,549,140 | |||||||||||||||||||
Proceeds from exercise of common stock warrants | $ 2,500,000 | |||||||||||||||||||
Number of warrant exercised | 2,086,479 | |||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Public offering, number of shares issued | 11,587 | |||||||||||||||||||
Preferred stock stated value per share | $ 1,000 | |||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Exercise price of warrants | $ 1.20 | |||||||||||||||||||
Maximum [Member] | Prefunded Warrants [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 120,000 | |||||||||||||||||||
Maximum [Member] | Investor Warrants [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Warrants exercisable percentage | 20.00% | |||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Exercise price of warrants | $ 1.25 | |||||||||||||||||||
Follow-on Public Offering [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Net cash proceeds from sale of securities | $ 592,000 | $ 6,600,000 | $ 13,300,000 | |||||||||||||||||
Private offering, number of common stock and warrants issued | 6,250,000 | 1,095,153 | ||||||||||||||||||
Stock price | $ 1.20 | $ 1.20 | $ 13.50 | |||||||||||||||||
Cost directly associated with offering | $ 1,400,000 | |||||||||||||||||||
Exercise price of warrants | $ 1.25 | $ 1.20 | $ 1.20 | |||||||||||||||||
Class of warrant or rights, term | 5 years 6 months | 5 years | 5 years | |||||||||||||||||
Issuance of warrants to purchase shares of common stock, grant date fair value | $ 9,700,000 | |||||||||||||||||||
Public offering, number of shares issued | 6,250,000 | |||||||||||||||||||
Public offering, number of common stock and warrants issued | 1,095,153 | |||||||||||||||||||
Private offering, number of common stock and warrants issued | 6,250,000 | 1,095,153 | ||||||||||||||||||
Proceeds from exercise of common stock warrants | $ 0 | $ 0 | ||||||||||||||||||
Purchase of common stock by underwriters to cover overallotments, number of shares | 538,867 | |||||||||||||||||||
Follow-on Public Offering [Member] | Maximum [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 6,250,000 | 1,095,153 | ||||||||||||||||||
Shelf Registration Statement [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Shelf registration statement expiration period | May 31, 2021 | May 31, 2021 | ||||||||||||||||||
Minimum public float limit for offering | $ 75,000,000 | $ 75,000,000 | ||||||||||||||||||
Shelf Registration Statement [Member] | Maximum [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Aggregate offering price | $ 50,000,000 | $ 50,000,000 | ||||||||||||||||||
Private Placement [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Exercise price of warrants | $ 3.16 | |||||||||||||||||||
Class of warrant or rights, term | 5 years | |||||||||||||||||||
Warrant exercisable for share of common stock | 1 | |||||||||||||||||||
Over-allotment Option [Member] | Warrant [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Public offering, number of shares issued | 915,000 | |||||||||||||||||||
Over-allotment Option [Member] | Maximum [Member] | ||||||||||||||||||||
Class Of Stock [Line Items] | ||||||||||||||||||||
Issuance of warrants to purchase shares of common stock | 937,500 |
Fair Value Measurement - Additi
Fair Value Measurement - Additional Information (Detail) - USD ($) | May 30, 2019 | Mar. 19, 2019 | Feb. 12, 2019 | Jan. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | May 31, 2019 | Feb. 28, 2019 | Aug. 13, 2018 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |||||||||
Fixed asset purchases as right-of-use asset finance lease obligations | $ 149,000 | $ 104,000 | |||||||
Estimated grant date fair value of warrants | $ 1.18 | $ 1.01 | $ 0.95 | $ 8.82 | |||||
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value | $ 1,800,000 | $ 6,000,000 | $ 6,800,000 | $ 9,700,000 | |||||
Exercise price of unregistered warrants | $ 1.25 | $ 1.20 | $ 1.20 | $ 1.20 | $ 4.53 | ||||
Class of warrant or rights, term | 5 years 6 months | 5 years | |||||||
Follow-on Public Offering [Member] | |||||||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |||||||||
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value | $ 9,700,000 | ||||||||
Exercise price of unregistered warrants | $ 1.25 | $ 1.20 | $ 1.20 | ||||||
Class of warrant or rights, term | 5 years 6 months | 5 years | 5 years | ||||||
Warrant Inducement Transaction [Member] | |||||||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |||||||||
Exercise price of unregistered warrants | $ 1.31 | ||||||||
Class of warrant or rights, term | 5 years 6 months | ||||||||
Maximum [Member] | |||||||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |||||||||
Issuance of unregistered warrants to purchase shares of common stock | 1,547,226 | 5,950,000 | 7,165,000 | 1,095,153 | |||||
Exercise price of unregistered warrants | $ 1.20 | ||||||||
Minimum [Member] | |||||||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |||||||||
Exercise price of unregistered warrants | $ 1.25 | ||||||||
Estimated Fair Value Measurements, Nonrecurring [Member] | Level 3 Inputs [Member] | |||||||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |||||||||
Fixed asset purchases as right-of-use asset finance lease obligations | $ 149,000 |
Fair Value Measurement - Assump
Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) | Jun. 30, 2019$ / shares | Mar. 19, 2019$ / shares | Jan. 18, 2019$ / shares | Sep. 20, 2018$ / shares |
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Stock price | $ 1.37 | $ 2.25 | $ 3.285 | |
January 30, 2018 Offering [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Stock price | $ 10.17 | |||
January 30, 2018 Offering [Member] | Exercise Price [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 15 | |||
January 30, 2018 Offering [Member] | Expected Dividend Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 0 | |||
January 30, 2018 Offering [Member] | Discount Rate-Bond Equivalent Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 2.48 | |||
January 30, 2018 Offering [Member] | Expected Life [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Expected life (in years) | 5 years | |||
January 30, 2018 Offering [Member] | Expected Volatility [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 99 | |||
February 12, 2019 Offering [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Stock price | $ 1.05 | |||
February 12, 2019 Offering [Member] | Exercise Price [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 1.20 | |||
February 12, 2019 Offering [Member] | Expected Dividend Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 0 | |||
February 12, 2019 Offering [Member] | Discount Rate-Bond Equivalent Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 2.49 | |||
February 12, 2019 Offering [Member] | Expected Life [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Expected life (in years) | 5 years | |||
February 12, 2019 Offering [Member] | Expected Volatility [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 147.7 | |||
March 19, 2019 Offering [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Stock price | $ 1.12 | |||
March 19, 2019 Offering [Member] | Exercise Price [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 1.25 | |||
March 19, 2019 Offering [Member] | Expected Dividend Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 0 | |||
March 19, 2019 Offering [Member] | Discount Rate-Bond Equivalent Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 2.44 | |||
March 19, 2019 Offering [Member] | Expected Life [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Expected life (in years) | 5 years 6 months | |||
March 19, 2019 Offering [Member] | Expected Volatility [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 140 | |||
May 30, 2019 Warrant Inducement Transaction [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Stock price | $ 1.29 | |||
May 30, 2019 Warrant Inducement Transaction [Member] | Exercise Price [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 1.31 | |||
May 30, 2019 Warrant Inducement Transaction [Member] | Expected Dividend Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 0 | |||
May 30, 2019 Warrant Inducement Transaction [Member] | Discount Rate-Bond Equivalent Yield [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 2.05 | |||
May 30, 2019 Warrant Inducement Transaction [Member] | Expected Life [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Expected life (in years) | 5 years 6 months | |||
May 30, 2019 Warrant Inducement Transaction [Member] | Expected Volatility [Member] | ||||
Warrant Fair Value Black Scholes Method [Line Items] | ||||
Exercise price | 145.9 |
Balance Sheet Details - Schedul
Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Fixed Assets | ||
Machinery and equipment | $ 2,823,938 | $ 2,818,583 |
Furniture and office equipment | 157,391 | 157,391 |
Computer equipment and software | 1,552,891 | 1,437,408 |
Leasehold improvements | 570,174 | 570,173 |
Financed equipment | 2,573,955 | |
Construction in process | 134,859 | 116,640 |
Total fixed assets, gross | 5,239,253 | 7,674,150 |
Less accumulated depreciation and amortization | (4,020,150) | (4,934,728) |
Total fixed assets, net | 1,219,103 | 2,739,422 |
Accrued Liabilities | ||
Accrued payroll | 194,917 | 255,426 |
Accrued vacation | 573,655 | 535,682 |
Accrued bonuses | 447,432 | 712,574 |
Accrued sales commissions | 87,224 | 62,767 |
Current portion of deferred rent | 158,342 | |
Accrued other | 187,580 | 203,602 |
Total accrued liabilities | $ 1,490,808 | $ 1,928,393 |
Balance Sheet Details - Additio
Balance Sheet Details - Additional Information (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Disposal of fixed assets | $ 0 | ||||
Fixed assets acquired | 86,476 | $ 72,356 | |||
Financed equipment gross | $ 2,573,955 | ||||
Depreciation expense | $ 228,856 | $ 177,401 | 450,984 | $ 357,173 | |
ASC Topic 842 [Member] | |||||
Fixed assets acquired | 139,000 | ||||
Financed equipment gross | 2,723,000 | 2,723,000 | 2,574,000 | ||
Accumulated depreciation related to financed equipment | $ 1,366,000 | $ 1,366,000 | $ 1,135,000 |
April 2014 Credit Facility - Ad
April 2014 Credit Facility - Additional Information (Detail) - USD ($) | May 30, 2019 | Mar. 19, 2019 | Feb. 12, 2019 | Jan. 30, 2018 | Apr. 30, 2014 | Dec. 31, 2014 | Feb. 28, 2019 | Aug. 13, 2018 |
Line of Credit Facility [Line Items] | ||||||||
Exercise price of unregistered warrants | $ 1.25 | $ 1.20 | $ 1.20 | $ 1.20 | $ 4.53 | |||
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value | $ 1,800,000 | $ 6,000,000 | $ 6,800,000 | $ 9,700,000 | ||||
Oxford Finance LLC [Member] | Common Stock [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Warrant issued to lender | 588 | |||||||
Exercise price of unregistered warrants | $ 424.80 | |||||||
Warrant term | 10 years | |||||||
Oxford Finance LLC [Member] | First Term Loan [Member] | ||||||||
Line of Credit Facility [Line Items] | ||||||||
Net cash proceeds on term loan | $ 4,898,000 | |||||||
Line of Credit Facility fees amount payable | $ 50,000 | |||||||
Line of Credit Facility, interest rate during period | 7.95% | |||||||
Percentage of final interest payment due at maturity | 5.50% | |||||||
Line of credit facility, maturity date | Jul. 1, 2018 | |||||||
Issuance costs | $ 102,000 | |||||||
Net proceeds from credit facility | 4,898,000 | |||||||
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value | $ 233,000 |
Leases - Additional Information
Leases - Additional Information (Detail) | Feb. 01, 2019USD ($) | Jan. 31, 2019USD ($)mo | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | Jan. 01, 2019USD ($) | Dec. 31, 2018USD ($) |
Leases [Line Items] | ||||||||
Finance lease right-of-use assets | $ 1,357,206 | $ 1,357,206 | ||||||
Financed equipment | $ 2,573,955 | |||||||
Total proceeds from equipment financing commitment | $ 149,000 | |||||||
Finance lease transaction, frequency of payments | monthly | |||||||
Finance lease transaction, number of installments payments | mo | 36 | |||||||
Finance lease transaction, monthly installments of principal and interest payments | $ 5,013 | |||||||
Finance lease transaction, total amount to be repaid | $ 180,000 | |||||||
Finance lease transaction, commitment period | 2022-02 | |||||||
Operating lease monthly payments | 711,624 | |||||||
Operating lease, right-of-use asset | 1,337,240 | 1,337,240 | ||||||
Operating lease liability | $ 1,533,091 | $ 1,533,091 | ||||||
Finance lease, weighted average remaining lease term | 3 years 2 months 8 days | 3 years 2 months 8 days | ||||||
Operating lease, weighted average remaining lease term | 1 year 1 month 2 days | 1 year 1 month 2 days | ||||||
Finance lease, weighted average discount rate, percent | 21.17% | 21.17% | ||||||
Operating lease, weighted average discount rate, percent | 4.50% | 4.50% | ||||||
Right of use assets in exchange for finance lease liabilities | $ 149,000 | |||||||
ASC Topic 842 [Member] | ||||||||
Leases [Line Items] | ||||||||
Finance lease right-of-use assets | $ 1,400,000 | |||||||
Financed equipment | $ 2,723,000 | 2,723,000 | 2,574,000 | |||||
Accumulated depreciation related to financed equipment | 1,366,000 | 1,366,000 | $ 1,135,000 | |||||
Depreciation expense related to equipment under finance leases | $ 89,000 | $ 89,000 | $ 231,000 | $ 156,000 | ||||
Operating lease transaction, frequency of payments | monthly cash payment | |||||||
Operating lease monthly payments | $ 120,000 | |||||||
Operating lease term | Jul. 31, 2020 | |||||||
Operating lease, right-of-use asset | 1,930,000 | |||||||
Operating lease liability | $ 2,201,000 | |||||||
Operating lease incremental borrowing rate | 4.50% | |||||||
ASC Topic 842 [Member] | Net Machinery and Equipment [Member] | ||||||||
Leases [Line Items] | ||||||||
Finance lease right-of-use assets | $ 1,400,000 | |||||||
Minimum [Member] | ASC Topic 842 [Member] | ||||||||
Leases [Line Items] | ||||||||
Financed equipment useful life | 3 years | 3 years | ||||||
Maximum [Member] | ASC Topic 842 [Member] | ||||||||
Leases [Line Items] | ||||||||
Financed equipment useful life | 7 years | 7 years |
Leases - Schedule of Right-Of-U
Leases - Schedule of Right-Of-Use Lease Assets (Detail) | Jun. 30, 2019USD ($) |
Lease right-of-use assets: | |
Operating | $ 1,337,240 |
Finance | 1,357,206 |
Total | $ 2,694,446 |
Leases - Schedule of Current Po
Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) | Jun. 30, 2019USD ($) |
Current portion of lease liabilities: | |
Operating | $ 1,411,385 |
Finance | 635,028 |
Total | $ 2,046,413 |
Leases - Schedule of Long-Term
Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) | Jun. 30, 2019USD ($) |
Long-term portion of lease liability: | |
Operating | $ 121,706 |
Finance | 861,713 |
Total | $ 983,419 |
Leases - Schedule of Lease Expe
Leases - Schedule of Lease Expense (Detail) - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2019 | Jun. 30, 2019 | |
Finance lease cost | ||
Amortization of right-of-use assets | $ 119,599 | $ 229,929 |
Interest on lease liabilities | 63,574 | 125,548 |
Operating lease cost | 318,005 | 636,010 |
Total | $ 501,178 | $ 991,487 |
Leases - Schedule of Remaining
Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail) | Jun. 30, 2019USD ($) |
Financing Lease Minimum Payment Abstract | |
2019 | $ 351,616 |
2020 | 611,772 |
2021 | 365,168 |
2022 | 268,056 |
Thereafter | 286,746 |
Total payments | 1,883,358 |
Less amount representing interest | (388,607) |
Present value of payments | 1,494,751 |
Financing Lease Maintenance and Sales Tax Obligation Payments Abstract | |
2019 | 46,833 |
2020 | 77,298 |
2021 | 56,136 |
2022 | 62,778 |
Thereafter | 45,710 |
Total payments | 288,755 |
Present value of payments | 288,755 |
Operating Lease Minimum Payment Abstract | |
2019 | 718,740 |
2020 | 855,136 |
Total payments | 1,573,876 |
Less amount representing interest | (40,785) |
Present value of payments | $ 1,533,091 |
Leases - Supplemental Cash Flow
Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) - USD ($) | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Other information | ||
Operating cash flows from finance leases | $ 125,548 | |
Operating cash flows from operating leases | 711,624 | |
Financing cash flows from finance leases | $ 277,250 | $ 111,006 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Detail) | Jun. 17, 2019shares | Jun. 28, 2018shares | Jun. 30, 2019USD ($)shares | Jun. 30, 2018 | Jun. 30, 2019USD ($)Planshares | Jun. 30, 2018 | Apr. 30, 2019shares | Dec. 31, 2018USD ($)shares |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Number of equity incentive plans | Plan | 2 | |||||||
Total Shares Outstanding | 2,768,443 | 2,768,443 | 195,820 | |||||
Unrecognized share-based compensation expense, weighted-average recognition period | 2 years 4 months 24 days | |||||||
Minimum [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Estimated forfeitures rate | 0.00% | 0.00% | 0.00% | 0.00% | ||||
Maximum [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Estimated forfeitures rate | 8.00% | 8.00% | 8.00% | 8.00% | ||||
Stock Options [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Intrinsic value of options outstanding | $ | $ 0 | $ 0 | $ 0 | |||||
Intrinsic value of options exercisable | $ | 0 | 0 | 0 | |||||
Intrinsic value of options vested and unvested expected to vest | $ | 0 | 0 | $ 0 | |||||
RSUs [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Intrinsic value shares, RSUs outstanding | $ | 400 | 400 | ||||||
Intrinsic value amount, RSUs unvested and vested expected to vest | $ | $ 400 | $ 400 | ||||||
RSUs outstanding | 360 | 360 | 360 | |||||
Stock Options and RSUs [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Unrecognized share-based compensation expense, stock options | $ | $ 2,627,000 | $ 2,627,000 | ||||||
2013 Equity Incentive Plan [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Total stock options and RSUs authorized | 124,211 | 124,211 | ||||||
Common stock, shares authorized | 2,578,229 | |||||||
2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Total stock options and RSUs authorized | 3,064,098 | 3,064,098 | ||||||
Increase in number of shares of common stock authorized for issuance | 2,800,000 | 146,666 | ||||||
Stock options and RSUs issued | 2,681,587 | |||||||
Total Shares Outstanding | 2,650,970 | 2,650,970 | ||||||
Common stock, shares authorized | 382,511 | 382,511 | ||||||
2013 Equity Incentive Plan [Member] | Inducement shares [Member] | ||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||||
Total stock options and RSUs authorized | 118,368 | 118,368 | ||||||
Stock options and RSUs issued | 117,534 | |||||||
Total Shares Outstanding | 118,368 | 118,368 | ||||||
Common stock, shares authorized | 0 | 0 |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ||
Number of Shares Outstanding, Beginning Balance | 195,820 | |
Number of Shares, Granted | 2,586,329 | |
Number of Shares, Cancelled/forfeited/expired | (13,706) | |
Number of Shares Outstanding, Ending Balance | 2,768,443 | 195,820 |
Number of Shares, Vested and unvested expected to vest, Ending Balance | 2,652,838 | |
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance | $ 41.41 | |
Weighted Average Exercise Price Per Share, Granted | 0.91 | |
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired | 21.04 | |
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance | 3.67 | $ 41.41 |
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance | $ 3.78 | |
Weighted Average Remaining Contractual Term in Years, Outstanding | 9 years 9 months 3 days | 9 years 2 months 12 days |
Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest | 9 years 9 months 3 days |
Stock-Based Compensation - Assu
Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) | 6 Months Ended |
Jun. 30, 2019$ / shares | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Expected dividend yield | 0.00% |
Minimum [Member] | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Stock and exercise prices | $ 0.91 |
Discount rate-bond equivalent yield | 2.28% |
Expected life (in years) | 5 years |
Expected volatility | 128.00% |
Maximum [Member] | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Stock and exercise prices | $ 1.03 |
Discount rate-bond equivalent yield | 2.55% |
Expected life (in years) | 5 years 11 months 15 days |
Expected volatility | 149.00% |
Stock-Based Compensation - Su_2
Stock-Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member] | 6 Months Ended |
Jun. 30, 2019$ / sharesshares | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |
Number of Shares Outstanding, Beginning Balance | shares | 360 |
Number of Shares, Granted | shares | 0 |
Number of share, Vested and issued | shares | 0 |
Number of share, Forfeited | shares | 0 |
Number of Shares Outstanding, Ending Balance | shares | 360 |
Number of Shares, Vested and unvested expected to vest, Ending Balance | shares | 360 |
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares | $ 415.80 |
Weighted Average Grant Date Fair Value, Granted | $ / shares | 0 |
Weighted Average Grant Date Fair Value, Vested and issued | $ / shares | 0 |
Weighted Average Grant Date Fair Value, Forfeited | $ / shares | 0 |
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares | 415.80 |
Weighted Average Grant Date Fair Value, Vested and unvested expected to vest, Ending Balance | $ / shares | $ 415.80 |
Stock-Based Compensation - Effe
Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Stock Options [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | $ 224,641 | $ 151,366 | $ 327,100 | $ 334,532 |
Stock Options [Member] | Cost of revenues [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | 17,073 | 9,421 | 25,220 | 27,000 |
Stock Options [Member] | Research and Development Expenses [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | 36,922 | 35,873 | 65,116 | 73,020 |
Stock Options [Member] | General and Administrative Expenses [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | 145,037 | 81,284 | 192,618 | 186,458 |
Stock Options [Member] | Sales and Marketing Expenses [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | 25,609 | 24,788 | 44,146 | 48,054 |
RSUs [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | $ 224,641 | 173,694 | $ 327,100 | 398,957 |
RSUs [Member] | Cost of revenues [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | (1,552) | (18,802) | ||
RSUs [Member] | Research and Development Expenses [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | 3,561 | 13,576 | ||
RSUs [Member] | General and Administrative Expenses [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | 14,243 | 54,303 | ||
RSUs [Member] | Sales and Marketing Expenses [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Total stock-based compensation | $ 6,076 | $ 15,348 |
Common Stock Warrants Outstan_3
Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Class Of Warrant Or Right [Line Items] | ||
Number of Shares, Outstanding, Beginning Balance | 4,694,927 | |
Number of Shares, Issued | 14,662,226 | |
Number of Shares, Exercised | (4,155,430) | |
Number of Shares, Expired | (4,474) | |
Number of Shares, Outstanding, Ending Balance | 15,197,249 | 4,694,927 |
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance | $ 8.55 | |
Weighted Average Exercise Price Per Share, Issued | 1.23 | |
Weighted Average Exercise Price Per Share, Exercised | 1.20 | |
Weighted Average Exercise Price Per Share, Expired | 953.06 | |
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance | $ 3.08 | $ 8.55 |
Average Remaining Contractual Term (in years) | 4 years 8 months 12 days | 4 years 4 months 24 days |
Common Stock Warrants Outstan_4
Common Stock Warrants Outstanding - Equity-Classified Common Stock Warrants, Outstanding (Detail) - $ / shares | 6 Months Ended | ||||||
Jun. 30, 2019 | Mar. 19, 2019 | Feb. 28, 2019 | Feb. 12, 2019 | Dec. 31, 2018 | Aug. 13, 2018 | Jan. 30, 2018 | |
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 1.25 | $ 1.20 | $ 1.20 | $ 4.53 | $ 1.20 | ||
Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Total Shares Outstanding | 15,197,249 | 4,694,927 | |||||
Weighted Average Exercise Price 1.24 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 1.24 | ||||||
Total Shares Outstanding | 11,601,949 | ||||||
Weighted Average Contractual Life (in years) | 4 years 10 months 24 days | ||||||
Weighted Average Exercise Price 4.21 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 4.21 | ||||||
Total Shares Outstanding | 3,311,578 | ||||||
Weighted Average Contractual Life (in years) | 4 years 2 months 12 days | ||||||
Weighted Average Exercise Price 25.50 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 25.50 | ||||||
Total Shares Outstanding | 8,208 | ||||||
Weighted Average Contractual Life (in years) | 3 years 4 months 24 days | ||||||
Weighted Average Exercise Price 33.00 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 33 | ||||||
Total Shares Outstanding | 96,999 | ||||||
Weighted Average Contractual Life (in years) | 2 years 3 months 18 days | ||||||
Weighted Average Exercise Price 45.00 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 45 | ||||||
Total Shares Outstanding | 47,821 | ||||||
Weighted Average Contractual Life (in years) | 3 years 1 month 6 days | ||||||
Weighted Average Exercise Price 75.00 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 75 | ||||||
Total Shares Outstanding | 71,995 | ||||||
Weighted Average Contractual Life (in years) | 3 years 3 months 18 days | ||||||
Weighted Average Exercise Price 117.00 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 117 | ||||||
Total Shares Outstanding | 38,772 | ||||||
Weighted Average Contractual Life (in years) | 1 year 9 months 18 days | ||||||
Weighted Average Exercise Price 140.40 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 140.40 | ||||||
Total Shares Outstanding | 19,339 | ||||||
Weighted Average Contractual Life (in years) | 7 months 6 days | ||||||
Weighted Average Exercise Price 424.80 [Member] | Warrant [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Weighted Average Exercise Price | $ 424.80 | ||||||
Total Shares Outstanding | 588 | ||||||
Weighted Average Contractual Life (in years) | 4 years 9 months 18 days |
Common Stock Warrants Outstan_5
Common Stock Warrants Outstanding - Additional Information (Detail) | Jun. 30, 2019USD ($) |
Warrants And Rights Note Disclosure [Abstract] | |
Common stock warrants outstanding, intrinsic value | $ 0 |
Net Loss per Common Share - Sch
Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive common share equivalents | 18,437,462 | 1,445,990 |
Warrants Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive common share equivalents | 15,197,249 | 1,383,349 |
RSUs Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive common share equivalents | 360 | 360 |
Preferred Warrants Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive common share equivalents | 17 | 17 |
Convertible Preferred Stock Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive common share equivalents | 471,393 | |
Common Options Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive common share equivalents | 2,768,443 | 62,264 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | |||
Feb. 29, 2016 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Loss Contingencies [Line Items] | ||||||
Unconditional purchase commitment aggregate amount | $ 1,062,500 | $ 216,000 | $ 216,000 | |||
Unconditional purchase commitment payment terms | Quarterly | |||||
Unconditional purchase commitment period | May 31, 2020 | |||||
Total expense for sales tax and maintenance obligations | 23,000 | $ 27,000 | $ 47,000 | $ 50,000 | ||
Total amounts for future sales tax and maintenance obligations | 288,755 | 288,755 | ||||
Accrued Other Liabilities [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Sales tax and maintenance obligations incurred but not paid | $ 70,000 | $ 70,000 | $ 69,000 | |||
Minimum [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Unconditional purchase commitment, quarterly payment amount | $ 62,500 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) | 1 Months Ended |
Apr. 30, 2019USD ($) | |
Aegea Biotechnologies, Inc [Member] | |
Related Party Transaction [Line Items] | |
Reimbursement for shared patent costs | $ 26,000 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) - Investor Warrants [Member] | Jul. 15, 2019 | May 28, 2019 | Jul. 31, 2019 |
Subsequent Event [Line Items] | |||
Warrants exercisable date | Jul. 15, 2019 | ||
Subsequent Event [Member] | |||
Subsequent Event [Line Items] | |||
Percentage of common stock exercised for exchange of new warrants | 75.00% | 75.00% | |
Warrants exercisable date | Jul. 31, 2019 | Jul. 31, 2019 |